|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0018956,
umls-concept:C0038952,
umls-concept:C0079744,
umls-concept:C0087111,
umls-concept:C0183683,
umls-concept:C0344211,
umls-concept:C0439064,
umls-concept:C0439590,
umls-concept:C0439859,
umls-concept:C1096776,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1521721
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-7-19
|
|
pubmed:abstractText |
A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged <65 years (74 score 2, 38 score 3) entered the study protocol. There were five early and two late toxic deaths. Overall 90 patients (80%) reached clinical remission (CR); at a median 48 months follow-up, 87 (78%) patients are alive, 82 (73%) in continuous CR, with 4 year overall survival (OS) and event-free survival (EFS) projections of 76% (CI 68-85%) and 73% (CI 64-81%), respectively. There were no significant differences in OS and EFS between subgroups with Germinal-Center and Activated B-cell phenotype. Thus, life expectancy of younger patients with aaIPI 2-3 DLB-CL is improved with the early administration of rituximab-supplemented intensive chemotherapy compared with the poor outcome following conventional chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Mitoxantrone,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
pubmed-author:BoccadoroMM,
pubmed-author:BregniMM,
pubmed-author:CabrasAA,
pubmed-author:CalviRR,
pubmed-author:CaraccioloDD,
pubmed-author:CominoAA,
pubmed-author:CorradiniPP,
pubmed-author:DevizziLL,
pubmed-author:Di NicolaMM,
pubmed-author:FornariAA,
pubmed-author:GallaminiAA,
pubmed-author:GianniA MAM,
pubmed-author:Gruppo Italiano Terapie Innovative nei Linfomi,
pubmed-author:LadettoMM,
pubmed-author:MagniMM,
pubmed-author:MajolinoII,
pubmed-author:MirtlLL,
pubmed-author:NoveroDD,
pubmed-author:PattiCC,
pubmed-author:PescarolloAA,
pubmed-author:PonzoniMM,
pubmed-author:RemottiDD,
pubmed-author:RosatiTT,
pubmed-author:StellaMM,
pubmed-author:TarellaCC,
pubmed-author:ZanniMM,
pubmed-author:ZoliVV
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1802-11
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17554382-Adolescent,
pubmed-meshheading:17554382-Adult,
pubmed-meshheading:17554382-Antibodies, Monoclonal,
pubmed-meshheading:17554382-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17554382-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17554382-Cisplatin,
pubmed-meshheading:17554382-Combined Modality Therapy,
pubmed-meshheading:17554382-Cyclophosphamide,
pubmed-meshheading:17554382-Cytarabine,
pubmed-meshheading:17554382-Disease-Free Survival,
pubmed-meshheading:17554382-Etoposide,
pubmed-meshheading:17554382-Feasibility Studies,
pubmed-meshheading:17554382-Female,
pubmed-meshheading:17554382-Humans,
pubmed-meshheading:17554382-Lymphoma, B-Cell,
pubmed-meshheading:17554382-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:17554382-Male,
pubmed-meshheading:17554382-Melphalan,
pubmed-meshheading:17554382-Middle Aged,
pubmed-meshheading:17554382-Mitoxantrone,
pubmed-meshheading:17554382-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:17554382-Prospective Studies,
pubmed-meshheading:17554382-Transplantation, Autologous,
pubmed-meshheading:17554382-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
|
|
pubmed:affiliation |
Dip Medicina-Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy. corrado.tarella@unito.it
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
